Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Phase 3Recruiting
- Sponsor
- GSK
- Start
- Sep 2023
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of belimumab in systemic sclerosis-associated interstitial lung disease (SSc-ILD), sponsored by GSK. Started Sep 2023; status: recruiting.
02
Drugs
belimumab
03
Conditions
systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT05878717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878717.